theMednetRegister

Medical Oncology

ASCO 2025   

Questions discussed in this category



Papers discussed in this category

The Lancet. Oncology, 2025 Feb 13
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 21
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).
Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Feb 07
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Feb 03
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
N Engl J Med, 2021-04-01
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
The New England journal of medicine, 2023 Jun 03
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2025 Jun 02
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
The New England journal of medicine, 2025 Jun 02
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
J Clin Oncol, 2022 Jun 03
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
N Engl J Med,
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Lancet Oncol., 2020 Mar 12
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
The New England journal of medicine, 2025 Jun 01
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
The New England journal of medicine, 2025 Jun 01
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
N Engl J Med, 2018 Mar 29
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
N Engl J Med,
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Nat Med, 2020 Apr 06
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
The New England journal of medicine, 2024 Jun 02
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
The New England journal of medicine, 2024 Nov 28
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025 May 31
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.
The New England journal of medicine, 2024 Jun 06
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
Nature medicine, 2024 Sep 15
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.
The New England journal of medicine, 2025 May 30
Encorafenib, Cetuximab, and mFOLFOX6 in -Mutated Colorectal Cancer.
The New England journal of medicine, 2025 May 31
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
Lancet (London, England), 2025 May 31
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
N. Engl. J. Med., 2017-07-27
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
International journal of radiation oncology, biology, physics, 2014-03-01
Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.
Annals of oncology : official journal of the European Society for Medical Oncology, 2025 May 30
Dostarlimab and niraparib in primary advanced ovarian cancer.
Lancet (London, England), 2025 Jun 02
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Jun 02
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.
Neuro-oncology, 2013-10
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Lancet (London, England), 2025 Jun 02
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Archives of internal medicine, 2006-07-10
Low testosterone levels and the risk of anemia in older men and women.
The American journal of medicine, 1997-01
Inapparent polycythemia vera: an unrecognized diagnosis.
Blood, 2019 Jul 25
How I treat polycythemia vera.
N Engl J Med, 2004 Jan 8
Daily aspirin--only half the answer.
Haematologica, 2019 Aug 14
Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.
Blood Cancer J, 2018 Nov 12
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.
Annals of internal medicine, 2018 Jan 16
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.
Haematologica, 2019 Apr 04
Distinguishing essential thrombocythemia V617F from polycythemia vera: limitations of erythrocyte values.
Lancet (London, England), 1978 Dec 09
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.
The New England journal of medicine, 2024 Feb 22
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
The Journal of clinical investigation, 1950 Aug
Iron metabolism; hematopoiesis following phlebotomy; iron as a limiting factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011 Sep 12
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
JAMA, 1977 Nov 28
Microcytic polycythemia. Frequency of nonthalassemic causes.

Related Topics in Medical Oncology

Copyright © 2025 theMednet
All Rights Reserved.